GSK Pharma shares slipped over 2% in early trade on Friday after the company announced its second-quarter (Q2) results for FY2025. As of 9:44 AM, the shares were trading 2.46% lower at Rs 2,541.30.
On a consolidated year-on-year (YoY) basis, GSK Pharma’s revenue fell 3.1% to ₹980 crore, compared to ₹1,011 crore in the same quarter last year. However, EBITDA grew 4.4% to ₹336 crore from ₹322 crore, with margins improving to 34.3% from 31.8%, indicating better cost management and operational efficiency.
The company’s net profit increased 2% to ₹257 crore versus ₹253 crore a year ago, marking modest earnings growth despite softer sales.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
